Series A investment: Danish biotech company Neumirna Therapeutics secures EUR 20 million

Mazanti Transactions has advised Copenhagen-based biotech company Neumirna Therapeutics in connection with its EUR 20 million Series A funding. The investment round was co-led by Angelini Ventures and Invivo Partners, with participation from existing investors such as Innovestor’s Life Science Fund.

Founded in 2020 by Dr. Henrik Klitgaard, Prof. Sakari Kauppinen, and Lars Hellerung Christiansen, Neumirna Therapeutics is a biotechnology company focused on developing RNA-based therapies to treat neurological diseases.

The funding will primarily support the clinical validation of Neumirna Therapeutics's lead candidate, NMT-001, a disease-modifying treatment for drug-resistant epilepsy, and the further development of the company’s RNA therapy platform.

Mazanti Transactions advised Neumirna Therapeutics in connection with all aspects of the investment with a team led by Lars Lüthjohan.